AAV TRANSFER PLASMIDS
    4.
    发明申请

    公开(公告)号:WO2023009622A1

    公开(公告)日:2023-02-02

    申请号:PCT/US2022/038520

    申请日:2022-07-27

    IPC分类号: C12Q1/68 A61K35/76 C07H21/04

    摘要: Disclosed herein is a nucleic acid stuffer sequence comprising one or more of the following features: no CPG island and no more than four contiguous nucleobases of the same identity; wherein the nucleic acid stuffer sequences does not include an open reading frame greater than 20 amino acids in length. In some embodiments, the nucleic acid stuffer sequence comprises between about 40% and about 50% GC content. In some embodiments, the nucleic acid stuffer sequence does not comprise a restriction enzyme cleavage site. In some embodiments, the nucleic acid stuffer sequence has a length of about 100 nucleobases to about 5000 nucleobases.

    用于治疗癌症的组合疗法
    6.
    发明申请

    公开(公告)号:WO2023284597A1

    公开(公告)日:2023-01-19

    申请号:PCT/CN2022/104040

    申请日:2022-07-06

    摘要: 本申请提供了一种在有此需要的对象中治疗肿瘤/癌症和/或产生针对肿瘤/癌症的记忆免疫应答的方法,包括向所述对象施用有效量的PI3K抑制剂、溶瘤病毒以及PD-1抑制剂,其中,所述PI3K抑制剂、溶瘤病毒和PD-1抑制剂可以同时、分开或者顺序施用。本申请还提供一种包含PI3K抑制剂、溶瘤病毒和PD-1抑制剂、以及可药用载体的药物组合物,以及一种包含所述药物组合物和使用说明的药盒。

    DEVICE AND METHODS FOR ACNE THERAPEUTICS: ANTIBACTERIAL BACTERIOPHAGES AND ENGINEERED LYSINS

    公开(公告)号:WO2022261498A1

    公开(公告)日:2022-12-15

    申请号:PCT/US2022/033106

    申请日:2022-06-10

    IPC分类号: A61K35/76 A61P17/10 A61P31/04

    摘要: Recombinantly-modified Cutibacterium acnes- specific bacteriophage, and recombinantly modified bacteriophage-derived endolysin enzyme are provided. Such compositions, alone or in combination with other antimicrobial agents or immunomodulators, may be used in pharmaceutical compositions, particularly pharmaceutical compositions to treat acne, promote wound healing, inhibit the growth of biofilms and to decrease the likelihood of, prevent or treat surgical related infections. The present invention is particularly directed to such formulations that are compounded for topical administration to a subject or used for application to medical devices. In particular, such pharmaceutical compositions may be compounded for topical administration to a subject, or compounded for application to a medical device.